CBS Microglial Neuroimmune Axis

Overview

flowchart TD
    CBS_Microglial_Neuroimmune_Axi["CBS Microglial Neuroimmune Axis"]
    CBS_Microglial_Neuroimmune_Axi["represents"]
    CBS_Microglial_Neuroimmune_Axi -->|"related to"| CBS_Microglial_Neuroimmune_Axi
    style CBS_Microglial_Neuroimmune_Axi fill:#81c784,stroke:#333,color:#000
    CBS_Microglial_Neuroimmune_Axi["critical"]
    CBS_Microglial_Neuroimmune_Axi -->|"related to"| CBS_Microglial_Neuroimmune_Axi
    style CBS_Microglial_Neuroimmune_Axi fill:#81c784,stroke:#333,color:#000
    CBS_Microglial_Neuroimmune_Axi["underappreciated"]
    CBS_Microglial_Neuroimmune_Axi -->|"related to"| CBS_Microglial_Neuroimmune_Axi
    style CBS_Microglial_Neuroimmune_Axi fill:#81c784,stroke:#333,color:#000
    style CBS_Microglial_Neuroimmune_Axi fill:#4fc3f7,stroke:#333,color:#000

The microglial neuroimmune axis represents a critical but underappreciated component of Corticobasal Syndrome (CBS) pathophysiology. While 4R-tauopathies like CBS and Progressive Supranuclear Palsy (PSP) are primarily defined by their tau pathology, accumulating evidence demonstrates that microglia—the resident immune cells of the central nervous system—play a pivotal role in disease progression, propagation of pathology, and therapeutic response. Single-cell transcriptomics studies from 2023-2024 have revealed disease-specific microglial states that differ markedly between CBS and other neurodegenerative conditions

Microglia in CBS exist in a complex and dynamic state, shaped by interactions with tau protein aggregates, TDP-43 pathology, neuronal damage signals, and the broader neuroimmune environment. Understanding this microglial landscape is essential for developing disease-modifying therapies that target neuroinflammation rather than merely addressing protein pathology.

Microglial Biology in the Normal Brain

Origin and Maintenance

Microglia arise from yolk-sac progenitors during embryonic development and seed the developing brain before the establishment of the blood-brain barrier. Unlike peripheral macrophages, microglia are self-renewing through local proliferation, with minimal contribution from bone-marrow-derived cells in the healthy adult brain^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}. This tissue-resident nature means that microglial populations in CBS have been present since early development, undergoing decades of interaction with the brain parenchyma before disease onset.

In the normal brain, microglia perform essential homeostatic functions:

• Synaptic surveillance and remodeling: Microglial processes continuously monitor synapses through P2Y12 receptor-dependent pathways, enabling activity-dependent synaptic pruning during development and experience-dependent plasticity throughout life^{3P2Y12 receptor-dependent microglial process extension in CBS2024 · Glia · PMID 38483412Open reference}

• Brain immune surveillance: Pattern recognition receptors (TLRs, NLRs) allow microglia to detect pathogens, damage-associated molecular patterns (DAMPs), and misfolded proteins

• Metabolic support: Microglia provide metabolic support to neurons through lactate shuttling and metabolic coupling

• Extracellular matrix remodeling: Matrix metalloproteinases (MMPs) secreted by microglia participate in neural circuit refinement

Key Microglial Receptors and Signaling Pathways

The microglial response in CBS is shaped by several key receptor systems:

Microglial States in CBS: Single-Cell Evidence

The Neurodegeneration-Associated Microglia (DAM) Program

A landmark framework from Keren-Shaul et al. described a continuum of microglial activation states in neurodegenerative disease^{5A unique microglia type associated with restricting Alzheimer's disease2017 · Cell · DOI 10.1016/j.cell.2017.05.018Open reference}. The neurodegenerative-associated microglia (DAM) program represents a protective response characterized by:

1. Stage 1 (intermediate): Downregulation of homeostatic genes (CX3CR1, P2Y12) and upregulation of DAM genes (TREM2, Apoe, Itgax)

2. Stage 2 (DAM): Full activation of a disease-associated transcriptional program including Lpl, Ctsd, Timp2, and genes involved in lipid metabolism and phagocytosis

In CBS, the DAM program shows distinctive features that differ from Alzheimer’s Disease (AD) and Parkinson’s Disease^{6Neurodegeneration-associated microglia (DAM) in corticobasal syndrome2022 · Acta Neuropathol Commun · PMID 35850738Open reference}:

• Early TREM2 engagement: DAM transition occurs at lower tau burden than in AD, suggesting more rapid microglial activation in response to 4R-tau pathology

• Dysmetabolic phenotype: CBS microglia show strong Lpl (lipoprotein lipase) upregulation, consistent with active phagocytosis of lipid-rich myelin debris from affected white matter

• Limited Trem2-dependence: Unlike AD, where TREM2 loss dramatically impairs the DAM program, CBS microglia can achieve partial DAM activation even in the presence of TREM2 risk variants^{7TREM2 genetic variants influence CBS susceptibility and inflammation2024 · Acta Neuropathol · PMID 38353821Open reference}

CBS-Specific Microglial Transcriptional States

Single-cell RNA sequencing studies in CBS and PSP have revealed at least five distinct microglial states^{1Microglial phenotypes in CBS and PSP based on single-cell analysis2024 · Acta Neuropathol Commun · PMID 38790123Open reference8Single-cell RNA-seq of microglia in corticobasal degeneration2023 · Nat Neurosci · DOI 10.1038/s41593-023-01300-4Open reference}:

1. Homeostatic microglia (HM): Found predominantly in unaffected regions; express CX3CR1, P2Y12, Tmem119

2. DAM-1 microglia: Transition state with partial downregulation of homeostatic genes

3. DAM-2 microglia: Full DAM program, highest in affected cortical and subcortical regions

4. Inflammatory microglia (IM): Strongly upregulated pro-inflammatory genes (IL1B, TNF, CCL2); associated with active neurodegeneration

5. Senescence-associated microglia (SAM): Upregulated Cdkn1a (p21), Cdkn2a (p16), SA-beta-gal; associated with aging and chronic neurodegeneration^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}0

Regional Distribution of Microglial States

The distribution of microglial states in CBS follows the characteristic asymmetric pattern of the disease^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}1:

• Motor cortex (Brodmann areas 4, 6): High DAM-2 frequency (~40%), moderate IM (~15%), reflecting active tau burden and neuronal loss

• Basal ganglia (putamen, globus pallidus): Dominant IM state (~25%), consistent with severe neuroinflammation in subcortical structures

• Brainstem (substantia nigra, colliculi): Mixed DAM/SAM pattern, reflecting chronic progressive degeneration

• Contralateral (less affected) hemisphere: Predominantly HM and DAM-1, indicating earlier disease stage

TREM2 Signaling in CBS

TREM2 Biology

Triggering receptor expressed on myeloid cells 2 (TREM2) is a surface receptor predominantly expressed on microglia and macrophages. TREM2 signaling promotes microglial survival, enhances phagocytosis of apoptotic cells and protein aggregates, and drives the transition to the DAM program^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}2.

TREM2 ligands include:

• Lipids: Phosphatidylserine, oxidized LDL, myelin lipids

• APOE: Lipidated APOE particles

• PSAP (prosaposin): Lysosomal saposin proteins

• Anionic ligands: Bacterial and viral components

TREM2 Genetic Variants in CBS

Common and rare TREM2 variants influence CBS susceptibility and microglial function^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}3:

• rs75932628 (TREM2 R47H): Associated with increased CBS risk and impaired microglial phagocytosis of tau aggregates

• rs20233084 (TREM2 I87V): Modulates microglial inflammatory response and disease progression

• Rare loss-of-function variants: Associated with Nasu-Hakola disease and increased neurodegenerative risk

The impact of TREM2 variants on CBS differs from AD: in AD, R47H dramatically increases risk (~3-4x), whereas in CBS the effect is more modest (~1.5-2x), suggesting that 4R-tau pathology can engage microglial responses even without full TREM2 signaling^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}4.

Therapeutic Targeting of TREM2

TREM2 represents a promising therapeutic target for CBS^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}5:

1. Agonist antibodies: TREM2-activating antibodies (AL002, AZD0323) enhance microglial phagocytosis and have shown efficacy in mouse models

2. Small molecule agonists: TREM2-peptidomimetic agonists promoting DAGL-dependent TREM2 activation

3. APOE-targeting: Reducing lipidated APOE, a TREM2 ligand, can modulate microglial activation

4. DAM-promoting strategies: Boosting the transition from IM to DAM-2 through colony-stimulating factor 1 receptor (CSF1R) agonism

Tau-Microglia Interactions

Phagocytosis of Tau Aggregates

Microglia actively phagocytose extracellular and cell-associated tau species. However, this process is often ineffective in 4R-tauopathies, leading to a cycle of uptake, incomplete degradation, and re-release of tau fragments^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}6^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}7:

• Uptake mechanisms: Microglia take up tau via macropinocytosis, receptor-mediated endocytosis (TREM2, LDL receptor family), and exosome-mediated transfer

• Degradation pathways: Phagocytosed tau is degraded through the autolysosomal system; impaired autophagosome-lysosome fusion in CBS microglia leads to incomplete degradation

• Re-release: Tau fragments that escape degradation can be re-released in exosomes, contributing to prion-like propagation

Tau-Induced Microglial Activation

Tau aggregates directly activate microglia through multiple pathways^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}8:

1. TLR4/NF-κB pathway: Extracellular tau activates toll-like receptor 4, driving production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)

2. NLRP3 inflammasome: Tau aggregates trigger NLRP3 activation, leading to caspase-1 activation and IL-1β release

3. IFN response pathway: Tau-stimulated microglia upregulate interferon-stimulated genes (ISGs), suggesting an antiviral-like response program

4. Complement activation: Microglia produce complement components (C1q, C3, C4) that drive synaptic loss and facilitate tau propagation^{2Physiology of microglia2011 · Physiol Rev · DOI 10.1152/physrev.00011.2010Open reference}9

The Tau-Phagocytosis Paradox

A key paradox in CBS is that despite high microglial activation, tau pathology continues to propagate. Potential explanations include:

• Phagocytic overload: Tau burden exceeds microglial clearance capacity

• Impaired lysosomal function: CBS-associated microglial lysosomal impairment prevents effective tau degradation

• Anti-phagocytic signaling: Tau aggregates can engage CD47 (“don’t eat me”) signals that inhibit phagocytosis

• Strain-specific resistance: 4R-tau filaments in CBS may be more resistant to proteolytic degradation than 3R-tau in AD

TDP-43 and Microglial Interactions

While the primary focus of CBS microglia research has been on tau pathology, a significant subset of CBS cases (~30-40%) also feature TDP-43 pathology

• TDP-43 uptake: Microglia can take up extracellular TDP-43 aggregates through mechanisms similar to tau uptake

• TDP-43 in activated microglia: TDP-43 can translocate to the cytoplasm in activated microglia, where it may influence gene expression

• Pro-granulin crosstalk: In CBS with GRN mutations, microglial TREM2 signaling interacts with progranulin deficiency to drive neurotoxic inflammation

• ALS overlap: The TDP-43-microglia interface in CBS overlaps significantly with Amyotrophic Lateral Sclerosis (ALS), suggesting shared therapeutic targets

Cytokine and Complement Profiles in CBS

Pro-inflammatory Cytokines

CBS patients show elevated cerebrospinal fluid (CSF) and plasma levels of several pro-inflammatory cytokines^{3P2Y12 receptor-dependent microglial process extension in CBS2024 · Glia · PMID 38483412Open reference}1:

Anti-inflammatory and Regulatory Cytokines

Counter-regulatory cytokines modulate the inflammatory response in CBS:

• IL-10: Elevated in CBS CSF; dampens microglial activation but may be insufficient to prevent disease progression

• TGF-β1: Critical regulator of microglial phenotype; elevated in CBS but signaling may be impaired at the receptor level^{3P2Y12 receptor-dependent microglial process extension in CBS2024 · Glia · PMID 38483412Open reference}2

• IL-4: Can promote neuroprotective A2 astrocyte phenotype; relatively reduced in CBS vs AD

Complement Cascade Activation

The complement system is strongly activated in CBS, particularly the classical pathway^{3P2Y12 receptor-dependent microglial process extension in CBS2024 · Glia · PMID 38483412Open reference}3:

• C1q: Initiates complement cascade; localizes to synapses and tau inclusions in CBS brain tissue

• C3a/C5a (anaphylatoxins): Pro-inflammatory fragments that recruit and activate microglia

• C5b-9 (MAC): Membrane attack complex; direct neuronal killing

• C4: Particularly elevated in CBS vs PSP; correlates with cortical tau burden

Complement activation in CBS drives both synaptic loss (through C1q-mediated tagging of synapses for microglial phagocytosis) and tau propagation (through C3-fragment deposition that facilitates protein aggregate uptake).

TSPO PET Imaging of Microglial Activation

TSPO Biology and Radioligands

Translocator protein (TSPO) is a mitochondrial receptor highly expressed in activated microglia. TSPO PET imaging enables in vivo quantification of neuroinflammation^{3P2Y12 receptor-dependent microglial process extension in CBS2024 · Glia · PMID 38483412Open reference}4^{3P2Y12 receptor-dependent microglial process extension in CBS2024 · Glia · PMID 38483412Open reference}5:

• 11C-PK11195: First-generation TSPO ligand; high baseline signal limits quantification

• 11C-PBR28 / 18F-GE180: Second-generation ligands with improved specificity

• 18F-AP-07: Third-generation with enhanced signal-to-noise

TSPO PET Findings in CBS

TSPO PET studies in CBS reveal characteristic patterns^{3P2Y12 receptor-dependent microglial process extension in CBS2024 · Glia · PMID 38483412Open reference}6^{3P2Y12 receptor-dependent microglial process extension in CBS2024 · Glia · PMID 38483412Open reference}7:

1. Asymmetric cortical signal: TSPO binding is significantly elevated in the more affected hemisphere, corresponding to clinical asymmetry

2. Subcortical dominance: Highest TSPO signal in basal ganglia (putamen > globus pallidus), exceeding cortical signal

3. Brainstem involvement: Moderate TSPO elevation in midbrain and pons, consistent with disease spread

4. Correlations: TSPO signal correlates with clinical severity (MDS-UPDRS III), disease duration, and CSF neurofilament light chain (NfL) levels

5. Longitudinal progression: TSPO signal increases over 12-24 months, tracking with clinical decline^{3P2Y12 receptor-dependent microglial process extension in CBS2024 · Glia · PMID 38483412Open reference}8

Comparison with PSP and AD

Microglial Synaptic Pruning in CBS

Physiologic Synaptic Pruning

Microglia maintain synaptic homeostasis through activity-dependent pruning of synapses, primarily mediated by:

• CX3CR1-CX3CL1 signaling: Neuronal fractalkine (CX3CL1) maintains microglial surveillance and limits excessive pruning

• Complement tagging: C1q and C3 tag synapses for elimination; microglia then phagocytose via CR3 (CD11b/CD18)

• P2Y12-mediated process extension: Microglia physically contact synapses and assess their activity state^{3P2Y12 receptor-dependent microglial process extension in CBS2024 · Glia · PMID 38483412Open reference}9

Dysregulated Pruning in CBS

In CBS, microglial synaptic pruning becomes dysregulated, contributing to early synaptic loss^{4TREM2-dependent microglial states in neurodegenerative disease2022 · Nat Rev Neurol · DOI 10.1038/s41582-022-00700-0Open reference}0:

• Early pruning onset: Synaptic loss (measured by CSF neurogranin, SV2A PET) occurs early in CBS, before severe motor symptoms

• Complement-dependent: C1q and C3 are elevated in CBS brain tissue and co-localize with synapses

• TREM2 connection: TREM2 signaling normally limits complement-dependent pruning; TREM2 dysfunction in CBS variants may disinhibit pruning

• Link to cognitive symptoms: Synaptic loss correlates with cognitive impairment in CBS, even in early disease

Microglial Senescence in CBS

Senescence-Associated Phenotype

A subset of CBS microglia adopt a senescence-associated phenotype that contributes to chronic neuroinflammation and impaired tissue repair^{4TREM2-dependent microglial states in neurodegenerative disease2022 · Nat Rev Neurol · DOI 10.1038/s41582-022-00700-0Open reference}1:

• p21/p16 upregulation: CDK inhibitors drive cell cycle arrest

• SA-β-gal activity: Detectable in affected brain regions

• SASP (senescence-associated secretory phenotype): Secretion of IL-6, IL-8, TNF-α, and matrix metalloproteinases

• Limited proliferation: Senescent microglia cannot expand to compensate for tissue damage

Causes of Microglial Senescence in CBS

1. Chronic tau exposure: Prolonged exposure to tau aggregates drives replicative senescence

2. Oxidative stress: Oxidative damage to microglial DNA and organelles

3. Mitochondrial dysfunction: Impaired energy metabolism limits cellular maintenance

4. Aging: CBS typically presents in the 6th-7th decade; age-related senescence compounds disease-related changes

Therapeutic Targeting of the Microglial Axis

Clinical-Stage Agents

Several microglial-targeting strategies are in clinical development or recently completed trials^{4TREM2-dependent microglial states in neurodegenerative disease2022 · Nat Rev Neurol · DOI 10.1038/s41582-022-00700-0Open reference}2:

Repurposed Approaches

Several approved drugs have microglial effects relevant to CBS:

• Minocycline: Antibiotic with anti-inflammatory microglial effects; mixed results in ALS/PD trials

• Anakinra (IL-1Ra): IL-1 receptor antagonist; blocks IL-1β signaling; used in autoinflammatory conditions

• Sargramostim (GM-CSF): Hematopoietic growth factor; promotes anti-inflammatory microglial phenotype

• Aspirin/NSAIDs: COX inhibitors reduce prostaglandin-mediated neuroinflammation

Emerging Strategies

1. Progranulin therapy: For CBS with GRN mutations, progranulin replacement or upregulation approaches

2. CSF1R agonism: Promoting microglial survival and the DAM program

3. Lipid metabolism modulation: Targeting Lpl and other lipid-handling genes upregulated in CBS microglia

4. Complement inhibition: C1q or C3 blockade to reduce synaptic loss and tau propagation

5. Senolytics: Targeting senescent microglia (e.g., senolytic BCL-2 inhibitors)

Interaction with Astrocyte Reactivity

Microglia and astrocytes form a tightly coupled neuroimmune unit. In CBS, microglial activation drives astrocyte reactivity through secreted cytokines^{4TREM2-dependent microglial states in neurodegenerative disease2022 · Nat Rev Neurol · DOI 10.1038/s41582-022-00700-0Open reference}3:

• IL-1α, TNF-α, C1q: Microglial-secreted factors that induce the neurotoxic A1 astrocyte phenotype

• A1 astrocytes: Upregulate complement components (C3), which feed back to promote microglial synaptic pruning

• Astrocytic plaques in CBS: The characteristic ring-like GFAP-positive structures reflect intense microglial-astrocyte crosstalk

This creates a self-reinforcing neuroinflammatory loop: tau pathology activates microglia → microglia induce A1 astrocytes → A1 astrocytes damage neurons → neuronal damage further activates microglia.

Cross-Linked Pages

CBS Mechanism Pages

• Neuroinflammation in CBS — Broader neuroinflammatory landscape

• Astrocyte Reactivity in 4R-Tauopathies — Astrocyte-microglia crosstalk

• TDP-43 Pathology in CBS — TDP-43-microglia interactions

• CBS Autophagy-Lysosomal Pathway — Lysosomal dysfunction in CBS microglia

• CBS Selective Neuronal Vulnerability — Vulnerability to microglial-mediated damage

• CBS Single-Cell Transcriptomics — Single-cell evidence for microglial states

4R-Tauopathy Mechanism Pages

• 4R-Tauopathy Neuroimmune Comparison — Cross-disease neuroimmune patterns

• 4R-Tau CBS — 4R-tau pathology biology

• Glial Tau Pathology PSP/CBD — Glial involvement in CBS and PSP

Biomarker Pages

• CBS PSP CSF Biomarkers — CSF cytokines and inflammatory markers

• CBS PSP Imaging Biomarkers — TSPO PET imaging

• Neuroimmune PSP Biomarkers — Neuroimmune biomarkers in PSP

Therapeutic Pages

• CBS PSP Cure Roadmap — Therapeutic targeting of neuroimmune pathways

• Innate Immune Pattern Recognition 4R-Tauopathies — Pattern recognition receptors